​​​
  1. Claris Life gets USFDA nod for generic anesthetic injection

Claris Life gets USFDA nod for generic anesthetic injection

Drug firm Claris Lifesciences has received approval from the US health regulator for generic anesthetic Bupivacaine injection.

By: | New Delhi | Published: July 26, 2016 1:58 PM
Shares of Claris Lifesciences were trading at Rs 253.60 in the afternoon trade on BSE, up 1.02 per cent. Shares of Claris Lifesciences were trading at Rs 253.60 in the afternoon trade on BSE, up 1.02 per cent.

Drug firm Claris Lifesciences has received approval from the US health regulator for generic anesthetic Bupivacaine injection.

The company has received approval from the United States Food and Drug Administration (USFDA) for generic “Bupivacaine hydrochloride in 8.25 per cent dextrose injection USP 7.5 mg/mL, single dose ampules with 2 ml fill volumes,” Claris Lifesciences said in a BSE filing.

The injection is indicated for the production of local or regional anesthesia or analgesia for surgery, diagnostic and therapeutic procedures.

With this approval the company has 15 approvals and 25 under approval abbreviated new drug applications (ANDAs), Claris Lifesciences said.

The company expects more product approvals during the year, it added.

Shares of Claris Lifesciences were trading at Rs 253.60 in the afternoon trade on BSE, up 1.02 per cent.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Go to Top